Primary lymphoma of bone: an institutional experience

References

• Shannon J A, Bell D R, Levi J A, Wheeler H R, Boyle F M. Bone presentation of non-Hodgkin's lymphoma: experience at the Royal North Shore Hospital, Sydney; highlighting primary bone lymphoma. Aust NZ J Med 1994; 24: 701–704
   PubMedGoogle Scholar
• Dubey P, Chul S H, Besa P C, Fuller L, Cabanillas F, Murray J, et al. Localized primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys 1997; 37: 1087–1093
   PubMed Web of Science ®Google Scholar
• Oberling C. Les réticulosarcomes et les réticuloendothéliosarcomes de la moelles osseuse (sarcomes d'Ewing). Bull Assoc Fr Etude Cancer (Paris) 1928; 17: 259–296
   Google Scholar
• Parker F, Jackson H. Primary reticulum cell sarcoma of bone. Surg Gynaecol Obstet 1939; 68: 45–53
   Google Scholar
• Suryanarayan K, Shuster J J, Donaldson S S, Hutchison R E, Murphy S B, Link M P. Treatment of localized primary non-Hodgkin's lymphoma of bone in children: a pediatric oncology group study. J Clin Oncol 1999; 17: 456–459
   PubMed Web of Science ®Google Scholar
• Ostrowski M L, Unni K K, Banks P M, Shives T C, Evans R G, O'Connell M J, et al. Malignant lymphoma of bone. Cancer 1986; 58: 2646–2655
   PubMed Web of Science ®Google Scholar
• Desai S, Jambheka N A, Chitralekha S S, Advani S H. Primary lymphoma of bone: a clinicopathologic study of 25 cases reported over 10 years. J Surg Oncol 1991; 46: 265–269
   PubMed Web of Science ®Google Scholar
• Jaffe, E S, Harris, N L, Stein, H, Vardiman, J W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press. 2001
   Google Scholar
• Fairbanks R K, Bonner J A, Inwards C Y, Strickler J G, Habermann T H, Unni K K, et al. Treatment of stage IE primary lymphoma of bone. Int J Radiat Oncol Biol Phys 1993; 28: 363–372
   Web of Science ®Google Scholar
• Lewis V O, Primus G, Anastasi J, Doherty D, Montag A G, Peabody T D, et al. Oncologic outcomes of primary lymphoma of bone in adults. Clin Orthop Relat Res 2003; 415: 90–97
   PubMed Web of Science ®Google Scholar
• Clayton F, Butler J J, Ayala A G, Ro J Y, Zornoza J. Non-Hodgkin's lymphoma of bone. Cancer 1987; 60: 2494–2501
   PubMed Web of Science ®Google Scholar
• Ramadan K M, Shenkier T, Sehn L H, Gascoyne R D, Connors J M. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 2007; 18: 129–135
   PubMed Web of Science ®Google Scholar
• Carbone P P, Kaplan H S, Musshoff K, Smithers D W, Tubianna M. Report of the committee on Hodkgin's disease staging classification. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Shipp M A, Harrington D P, Anderson J R, Armitage J O, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Baar J, Burkes R L, Bell R, Blacksetin M D, Fernandes B, Langer F. Primary non-Hodgkin's lymphoma of bone: a clinicopathologic study. Cancer 1994; 73: 1194–1199
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Fuegier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patient with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Sehn L H, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027–5033
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P, Chan J KC, Cleary M L, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• McKelvey E M, Gottlieb J A, Wilson H E, Haut A, Talley R W, Stephens R, et al. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Wilson W H, Bryant G, Bates S, Fojo A, Wittes R E, Steinberg S M, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573–1582
   PubMed Web of Science ®Google Scholar
• Shipp M A, Harrington D P, Klatt M M, Jochelson M S, Pinkus G S, Marshall J L, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757–765
   PubMed Web of Science ®Google Scholar
• Schein P S, DeVita VT Jr, Hubbard S, Chabner B A, Canellos G P, Young B C. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 1976; 85: 417–427
   PubMed Web of Science ®Google Scholar
• Mendenhall N P, Jones J J, Kramer B S, Hudson T M, Carter R L, Enneking W F, et al. The management of primary lymphoma of bone. Radiother Oncol 1987; 9: 137–145
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Vose J M. Current approaches to the management of non-Hodgkin's lymphoma. Sem Oncol 1998; 25: 483–491
   PubMed Web of Science ®Google Scholar
• Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 2006; 106: 2652–2656
   PubMed Web of Science ®Google Scholar